



Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice

Derek Weycker¹ Xiaoyan Li² Gail DeVecchis Wygant² Theodore Lee³ Melissa Hamilton²
Xuemei Luo⁴ Lien Vo² Jack Mardekian³ Xianying Pan⁵ Leah Burns² Mark Atwood¹
Ahuva Hanau¹ Alexander T. Cohen⁶

¹Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States

²Bristol-Myers Squibb, Lawrenceville, New Jersey, United States

³Pfizer Inc., New York, New York, United States

⁴Pfizer Inc., Groton, Connecticut, United States

⁵Bristol-Myers Squibb, Wallingford, Connecticut, United States

⁶Guy's and St. Thomas' Hospitals, London, United Kingdom

Address for correspondence Derek Weycker, PhD, Policy Analysis Inc. (PAI), Four Davis Court, Brookline, Massachusetts, 02445, United States (e-mail: dweycker@pai2.com).

Thromb Haemost 2018;118:e1–e2.

ERRATUM

The authors have brought to the publisher's attention that there were some errors in ► **Fig. 1** of the article and ► **Table 1** of the Supplementary Material published in the above article in *Thrombosis and Haemostasis*, Volume 118, Number 8, 2018 (DOI: 10.1055/s-0038-1673689). The corrected figure and table appear as follows:

DOI <https://doi.org/10.1055/s-0039-3400530>.
ISSN 0340-6245.

© 2020. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany




Fig. 1 Selection of patients receiving apixaban or warfarin as outpatient therapy for VTE. IVCF, inferior vena cava filter; OAC, oral anticoagulant; PAC, parenteral anticoagulant; VTE, venous thromboembolism.